Fidelity Investments
ZNTL icon

Fidelity Investments’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Fidelity Investments’s Portfolio ZNTL Stock Details ZNTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$664K Buy
283,917
+40,609
+17% +$105K ﹤0.01% 3011
2025
Q4 		$328K Buy
243,308
+40,003
+20% +$58.2K ﹤0.01% 3236
2025
Q3 		$307K Buy
203,305
+18,628
+10% +$27.9K ﹤0.01% 3205
2025
Q2 		$214K Buy
184,677
+2,487
+1% +$3.28K ﹤0.01% 3284
2025
Q1 		$290K Sell
182,190
-119
-0.1% -$257 ﹤0.01% 3111
2024
Q4 		$552K Sell
182,309
-4,893,528
-96% -$16M ﹤0.01% 2895
2024
Q3 		$18.7M Sell
5,075,837
-3,600,886
-42% -$13.1M ﹤0.01% 1730
2024
Q2 		$35.5M Sell
8,676,723
-1,967,301
-18% -$22M ﹤0.01% 1445
2024
Q1 		$168M Buy
10,644,024
+307,053
+3% +$4.22M 0.01% 858
2023
Q4 		$157M Buy
10,336,971
+843,075
+9% +$12.3M 0.01% 844
2023
Q3 		$190M Sell
9,493,896
-1,082,676
-10% -$27.5M 0.02% 717
2023
Q2 		$298M Buy
10,576,572
+1,663,821
+19% +$39.9M 0.03% 575
2023
Q1 		$153M Buy
8,912,751
+1,003,575
+13% +$20.3M 0.01% 820
2022
Q4 		$159M Buy
7,909,176
+339,570
+4% +$7.3M 0.02% 776
2022
Q3 		$164M Sell
7,569,606
-206,562
-3% -$5.65M 0.02% 751
2022
Q2 		$219M Buy
7,776,168
+1,033,474
+15% +$27.4M 0.02% 654
2022
Q1 		$311M Sell
6,742,694
-53,137
-0.8% -$2.87M 0.02% 618
2021
Q4 		$571M Buy
6,795,831
+37,896
+0.6% +$2.93M 0.04% 417
2021
Q3 		$450M Buy
6,757,935
+95,710
+1% +$5.52M 0.04% 462
2021
Q2 		$354M Buy
6,662,225
+506,183
+8% +$27.1M 0.03% 582
2021
Q1 		$267M Buy
6,156,042
+63,964
+1% +$2.75M 0.02% 656
2020
Q4 		$316M Buy
6,092,078
+3,234,158
+113% +$146M 0.03% 559
2020
Q3 		$93.4M Buy
2,857,920
+546,974
+24% +$19.2M 0.01% 939
2020
Q2 		$111M Buy
+2,310,946
New +$88.6M 0.01% 838

Other funds holding ZNTL

5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $273M AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return

Fidelity Investments's ZNTL Position: Q1 2026 in Review

Fidelity Investments increased its Zentalis Pharmaceuticals (ZNTL) stake by 17% in Q1 2026, buying an estimated $105K and bringing the position to 283,917 shares worth $664K. The position accounts for ﹤0.01% of the portfolio, ranked #3011.

Fidelity Investments first reported a position in ZNTL in Q2 2020 and has held it in 24 quarters since. The position peaked at $571M in Q4 2021. 102 funds tracked by Wall St. Rank hold ZNTL as of Q1 2026.

  • Fidelity Investments held 283,917 shares of Zentalis Pharmaceuticals worth $664K as of Q1 2026.
  • Fidelity Investments bought 40,609 Zentalis Pharmaceuticals shares in Q1 2026, an estimated $105K.
  • Zentalis Pharmaceuticals made up ﹤0.01% of Fidelity Investments's portfolio in Q1 2026, its #3011 holding.
  • Fidelity Investments first reported a position in Zentalis Pharmaceuticals in Q2 2020 and has held it in 24 quarters since.
  • Fidelity Investments's Zentalis Pharmaceuticals position peaked at $571M in Q4 2021.
  • 102 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q1 2026.

Based on Fidelity Investments's 13F filing for Q1 2026, filed 15 May 2026.